• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Incyte

    < Previous 1 2 3 4 Next >
    Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Tickers INCY
    Science Magazine Recognizes Incyte as #2 “Top Employer” of 2023
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
    From Incyte
    Via Business Wire
    Tickers INCY
    Data From Incyte’s Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)
    From Incyte
    Via Business Wire
    Tickers INCY
    New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of Clarity
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
    From Incyte
    Via Business Wire
    Tickers INCY REPL
    Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents
    From Incyte
    Via Business Wire
    Tickers INCY
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.